UNSPSC 51392211: Mivazerol or piroximone

This classification denotes an alpha-adrenergic agonist with the molecular formula C11H11N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5P1SSA8KD, chemically known as alpha-imidazol-4-yl-2,3-cresotamide but generally known as mivazerol, which bears US NIH Compound Identifier 60784. European Medicines Agency schedules Mivazerol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09015MIG.

The term MIVAZEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Mivazerol or piroximone bears US NLM identifiers UMLS ID C0071150 and NCI Concept Code C90921. SMILES: CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2.

UNSPSC 51392211 Mivazerol or piroximone is a Commodity code nominally indexing specific pharmaceutical agents, but recent state and local activity shows a mismatch between the code's abstract title and what is actually being procured. The Seminole County, Florida opportunity tagged to this code solicits Naloxone and Safe Drug Deactivation Systems — neither of which corresponds to the code's named compounds. The Texas Health and Human Services Commission's concurrent RFI on direct-to-manufacturer prescriptions similarly does not target mivazerol or piroximone specifically. State and local procurement offices appear to be using this code as a catch-all for certain pharmaceutical procurement, though the actual products bought diverge from the code's nominal scope. Recent activity shows health departments and state health agencies as the issuing bodies, but the code itself shows little targeted, substantive activity aligned to its stated commodity name.

The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2026, seeks annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract is structured for an initial two-year term with one-year renewal option and includes requirements for drug-free workplace certification, E-Verify compliance, and specified insurance coverage. The Texas HHS Commission's Request for Information (HHS0017013), posted April 3, 2026, explores vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, focusing on negotiated net pricing and outcomes-based contracting models. Geographic activity is limited to Florida and Texas in the recent opportunities block. The mismatch between the code's nominal scope and actual procurement suggests this code may not be the appropriate vehicle for pursuing pharmaceutical opportunities in state and local markets — vendors should verify code assignment in actual RFPs before investing pre-bid resources.